127 related articles for article (PubMed ID: 30033446)
41. Patients' and physicians' roles in detecting recurrent Hodgkin lymphoma following complete remission.
Bestawros A; Foltz L; Srour N; Savage KJ; Connors JM
Ann Oncol; 2013 May; 24(5):1359-63. PubMed ID: 23230136
[TBL] [Abstract][Full Text] [Related]
42. Primary cutaneous marginal zone B-cell lymphoma: response to treatment and disease-free survival in a series of 137 patients.
Servitje O; Muniesa C; Benavente Y; Monsálvez V; Garcia-Muret MP; Gallardo F; Domingo-Domenech E; Lucas A; Climent F; Rodriguez-Peralto JL; Ortiz-Romero PL; Sandoval J; Pujol RM; Estrach MT
J Am Acad Dermatol; 2013 Sep; 69(3):357-65. PubMed ID: 23796549
[TBL] [Abstract][Full Text] [Related]
43. Role of computed tomography on large B-cell non-Hodgkin's lymphoma follow-up and the risk of radiation-induced neoplasm: A retrospective cohort study.
Graña L; Calzado A; Hernández P; Rodríguez R
Eur J Radiol; 2016 Mar; 85(3):673-9. PubMed ID: 26860683
[TBL] [Abstract][Full Text] [Related]
44. Autologous transplantation for diffuse aggressive non-Hodgkin lymphoma in first relapse or second remission.
Vose JM; Rizzo DJ; Tao-Wu J; Armitage JO; Bashey A; Burns LJ; Christiansen NP; Freytes CO; Gale RP; Gibson J; Giralt SA; Herzig RH; Lemaistre CF; McCarthy PL; Nimer SD; Petersen FB; Schenkein DP; Wiernik PH; Wiley JM; Loberiza FR; Lazarus HM; van Biesen K; Horowitz MM
Biol Blood Marrow Transplant; 2004 Feb; 10(2):116-27. PubMed ID: 14750077
[TBL] [Abstract][Full Text] [Related]
45. Utility of a multiple serum biomarker test to monitor remission status and relapse in dogs with lymphoma undergoing treatment with chemotherapy.
Alexandrakis I; Tuli R; Ractliffe SC; Tappin SW; Foale RD; Roos A; Slater KJ
Vet Comp Oncol; 2017 Mar; 15(1):6-17. PubMed ID: 25319380
[TBL] [Abstract][Full Text] [Related]
46. Patterns and Timing of Initial Relapse in Pathologic Stage II Melanoma Patients.
Lee AY; Droppelmann N; Panageas KS; Zhou Q; Ariyan CE; Brady MS; Chapman PB; Coit DG
Ann Surg Oncol; 2017 Apr; 24(4):939-946. PubMed ID: 27804026
[TBL] [Abstract][Full Text] [Related]
47. The clinical value of follow-up examinations in childhood T-cell acute lymphoblastic leukemia and T-cell non-Hodgkin's lymphoma.
Huang L; Lequin M; Pieters R; van den Heuvel-Eibrink MM
Pediatr Blood Cancer; 2007 Apr; 48(4):468-72. PubMed ID: 16514610
[TBL] [Abstract][Full Text] [Related]
48. [Treatment outcomes and prognostic analyses of relapsed or refractory T-cell non-Hodgkin's lymphoma].
Gao Y; Huang HQ; Lin XB; Cai QQ; Pan ZH; Wang BF; Bu Q
Ai Zheng; 2007 Aug; 26(8):909-13. PubMed ID: 17697558
[TBL] [Abstract][Full Text] [Related]
49. Wide-field radiation therapy with or without chemotherapy for patients with Hodgkin disease in relapse after initial combination chemotherapy.
Uematsu M; Tarbell NJ; Silver B; Coleman CN; Rosenthal DS; Shulman LN; Canellos G; Weinstein H; Mauch P
Cancer; 1993 Jul; 72(1):207-12. PubMed ID: 7685241
[TBL] [Abstract][Full Text] [Related]
50. Results of radiotherapy and combined modality treatment in early stage high grade non-Hodgkin's lymphoma.
Frank C; Flentje M; Goldschmidt H; Hunstein W; Wannenmacher M
Strahlenther Onkol; 1994 Jul; 170(7):383-90. PubMed ID: 8052937
[TBL] [Abstract][Full Text] [Related]
51. Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients.
Zinzani PL; Tani M; Molinari AL; Stefoni V; Zuffa E; Alinari L; Gabriele A; Bonifazi F; Salvucci M; Tura S; Baccarani M
Haematologica; 2002 Aug; 87(8):816-21. PubMed ID: 12161357
[TBL] [Abstract][Full Text] [Related]
52. Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials.
Michot JM; Benajiba L; Faivre L; Baldini C; Haddag L; Bonnet C; Massard C; Bigot F; Bigenwald C; Verret B; Thomas ZAP; Varga A; Gazzah A; Hollebecque A; Ghez D; Lazarovici J; Balheda R; Jeanson A; Postel-Vinay S; Danu A; Soria JC; Paoletti X; Ribrag V
Invest New Drugs; 2018 Feb; 36(1):62-74. PubMed ID: 28597151
[TBL] [Abstract][Full Text] [Related]
53. Young adults diagnosed with Hodgkin lymphoma are at risk of relapsing late: a comprehensive analysis of late relapse in Hodgkin lymphoma.
Pinczés L; Miltényi Z; Illés Á
J Cancer Res Clin Oncol; 2018 May; 144(5):935-943. PubMed ID: 29468437
[TBL] [Abstract][Full Text] [Related]
54. What surveillance plan should be advised for patients in remission after completion of first-line therapy for advanced ovarian cancer?
Rustin GJ
Int J Gynecol Cancer; 2010 Oct; 20(11 Suppl 2):S27-8. PubMed ID: 20975357
[TBL] [Abstract][Full Text] [Related]
55. Integration of CT-Based Measurements into Surveillance PET/CT in Patients with Diffuse Large B Cell Lymphoma.
Lavi N; Shapira G; Zilberlicht A; Benyamini N; Farbstein D; Dann EJ; Bar-Shalom R; Avivi I
Isr Med Assoc J; 2016 Jul; 18(7):411-417. PubMed ID: 28471564
[TBL] [Abstract][Full Text] [Related]
56. Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT.
Spyridonidis A; Labopin M; Schmid C; Volin L; Yakoub-Agha I; Stadler M; Milpied N; Socie G; Browne P; Lenhoff S; Sanz MA; Aljurf M; Mohty M; Rocha V;
Leukemia; 2012 Jun; 26(6):1211-7. PubMed ID: 22290066
[TBL] [Abstract][Full Text] [Related]
57. High relapse rate in patients with MALT lymphoma warrants lifelong follow-up.
Raderer M; Streubel B; Woehrer S; Puespoek A; Jaeger U; Formanek M; Chott A
Clin Cancer Res; 2005 May; 11(9):3349-52. PubMed ID: 15867234
[TBL] [Abstract][Full Text] [Related]
58. ABVD alone and a PET scan complete remission negates the need for radiologic surveillance in early-stage, nonbulky Hodgkin lymphoma.
Hartridge-Lambert SK; Schöder H; Lim RC; Maragulia JC; Portlock CS
Cancer; 2013 Mar; 119(6):1203-9. PubMed ID: 23132361
[TBL] [Abstract][Full Text] [Related]
59. Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era.
Avivi I; Zilberlicht A; Dann EJ; Leiba R; Faibish T; Rowe JM; Bar-Shalom R
Am J Hematol; 2013 May; 88(5):400-5. PubMed ID: 23423884
[TBL] [Abstract][Full Text] [Related]
60. Incidence and risk factors for relapses in HIV-associated non-Hodgkin lymphoma as observed in the German HIV-related lymphoma cohort study.
Schommers P; Gillor D; Hentrich M; Wyen C; Wolf T; Oette M; Zoufaly A; Wasmuth JC; Bogner JR; Müller M; Esser S; Schleicher A; Jensen B; Stoehr A; Behrens G; Schultze A; Siehl J; Thoden J; Taylor N; Hoffmann C
Haematologica; 2018 May; 103(5):857-864. PubMed ID: 29439188
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
